Article

Presbyopia-correcting IOL receives high marks

Author(s):

The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.

Reviewed by William C. Christie, MD

The presbyopia-correcting IOL, (Tecnis Synergy Model ZFR00V, Johnson & Johnson Surgical Vision Inc), performed exceedingly well in 2 studies that used questionnaires to assess the surgeon and patient responses to the IOL performance, according to William Christie, MD, who is in private practice in Pittsburgh.

The lens received FDA approval in 2021.

“The Synergy IOL is the next-generation presbyopia-correcting IOL,” Christie commented.

The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches, Christie explained.

The investigators conducted 2 prospective studies, 1 a bilateral, multicenter, clinical trial that was carried out in Germany, Spain, Philippines, Singapore, and New Zealand referred to as the global study and 1 multicenter trial in the US at 15 sites in western Pennsylvania, referred to as the US study. The studies included adults who had less than 1.0 D of predicted postoperative corneal astigmatism and underwent bilateral crystalline lens removal and implantation with the IOL under study. Emmetropia was targeted in both eyes.

Questionnaire findings

The results in both studies showed that about 88% of the participants reported spectacle and contact lens independence at all distances.

Regarding patient satisfaction, 89% of the patients in the US study reported being completely or mostly satisfied with the performance of the IOL, and 81.1% in the global group reported being satisfied with the overall vision with not having to wear glasses.

Surgeon satisfaction with the clinical outcomes and surgical experience, registered 96.8% and 100%, respectively, in the global group.

The limited amount of spectacle wear time achieved with this IOL was the same between studies conducted in the US and globally and at different time points after surgery (3 months and 6 months) and led to high satisfaction rates among the patients and surgeons.

“Most importantly,” Christie commented, “the majority of patients were considered 20-happy.’”

William C. Christie, MD

E: wchristiemd@aol.com

This article is adapted from Christie’s presentation at the American Society of Cataract and Refractive Surgery’s recent annual meeting in Washington, DC. He is a consultant to Johnson + Johnson Surgical Vision.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
Alex Hacopian, MD, discusses a presbyopia-correcting IOL at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Parag Majmudar, MD, on bridging the gap between residency and real-world practice
Brett Bielory, MD, discusses his poster at the ASCRS annual meeting, which focuses on an under-diagnosed corneal pathology: neurotrophic keratitis.
© 2025 MJH Life Sciences

All rights reserved.